AGMT_ALL Registry

Registry and Biobank for the collection of clinical data and biomaterial from adult ALL patients

Synopsis

Short title: AGMT_ALL-Registry

Title: Registry and Biobank for the collection of clinical data and biomaterial from adult ALL patients

Status: open

Start: October 2012

Coordinating Investigator: Univ. Prof. Dr. Ulrich Jäger/ Assoc.-Prof. Priv. Doz. Dr. Alexander W. Hauswirth

NIS Number: NIS002823

Number of patients: 70 patients per year

Sponsor: AGMT gemeinnützige GmbH

Link to online CRF

Design

This registry is a retrospective and prospective, observational, multi-centre research initiative. Data will be collected from all sites in Austria willing to participate.

Objectives:

The aim of the ALL registry is to collect data regarding diagnosis, therapy and progression of disease for all Austrian ALL patients older than 18 years. These data should be collected during clinical routine treatment of the patients.
Following data should be collected:

  • Baseline data like initial diagnostic including subtype of ALL, histology, prognostic factors, immunophenotyp, cytology, molecular diagnostic
  • Induction therapy, SCT, experimental treatment
  • Supportive therapies
  • Inclusion in clinical studies
  • Response including MRD
  • Comorbidity
  • Quality of life

Inclusion/Exclusion Criteria

Inclusion Criteria:
  • Age 18 or older
  • Patient’s written informed consent
  • Acute lymphoblastic leukaemia (all types according WHO classification 2008)
  • Diagnosis of specific NHL subtypes (WHO classification) :
    • B-lymphoblastic lymphoma
    • T-lymphoblastic lymphoma
    • Burkitt´s lymphoma
    • Aggressive lymphoma with c-myc translocation
    • Other high risk lymphomas treated with ALL protocols

Due to the non-interventional design of the registry there are no exclusion criteria.

Register